ADAPTIVE MUTATION IS COMMON IN E.COLI.
The quickening of genetic mutation rates in bacteria may not only
happen when the microorganisms find themselves in strange and stressful
circumstances. A new report in Molecular Microbiology by . . .
CERUS INITIATES PHASE IB CLINICAL TRIAL FOR ACIT.
Cerus Corporation (Nasdaq:CERS), Corcord, Calif., has initiated a
Phase IB clinical trial for its allogeneic cellular immune therapy
(ACIT). The company's ACIT is being developed to improve stem . . .
GUAVA VIACOUNT FLEX ALLOWS NON-MAMMALIAN CELL
COUNT/ASSESSMENT.
With the Guava ViaCount Flex assay reagent, quick and reproducible
absolute cell count and viability assessments can now be done with
insect and other non-mammalian cells, announced Guava . . .
LOCUS LICENSES GP41 CRYSTAL STRUCTURE FROM CORNELL
RESEARCH.
Locus Pharmaceuticals, Inc., Blue Bell, Pa., a privately held
pharmaceutical company focused on developing novel, small molecule
therapeutics, has licensed from Cornell Research Foundation . . .
RXPEDITE TO MANAGE COMMERCIALIZATION OF FAMPRIDINE-SR.
Rxpedite(SM), an alliance between inChord Communications and
Cardinal Health (NYSE:CAH), has signed an agreement with Acorda
Therapeutics to manage the commercialization of Fampridine-SR, a . . .
NICOX TO REACQUIRE RIGHTS TO ASTRAZENICA CINOD CLASS OF
DRUGS.
NicOx S.A. (Nouveau Marche: NICOX), Sophia Antipolis, France, has
announced that it is to reacquire full rights to the new proprietary
class of anti-inflammatory and analgesic compounds, CINOD, . . .
EUROPEAN APPROVAL OF REMODULIN DELAYED.
United Therapeutics Corporation (NASDAQ:UTHR) has been informed
that the General Commission of the French Regulatory Agency has
recommended that Remodulin not be approved in France based . . .
BIORAL DELIVERY IMPROVES EFFICACY/REDUCES ASPIRIN SIDE
EFFECTS.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI), Newark,
N.J., has announced that results of animal studies show that the
patented cochleate based delivery system Bioral(TM), used with . . .
NUVELO ASSIGNS PATENTS TO SEQUENOM.
Nuvelo, Inc. (NASDAQ:NUVO), Sunnyvale, and SEQUENOM, Inc.
(NASDAQ:SQNM), San Diego, have signed a patent assignment and license
agreement. Under terms of the agreement, Nuvelo assigned SEQUENOM . . .
SCICLONE ENROLLS 500 PATIENTS IN FIRST OF HEPATITIS C
TRIALS.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), San Mateo, Calif.,
has completed the planned enrollment of 500 patients in the first of its
two phase 3 hepatitis C (HCV) clinical trials evaluating . . .
IDUN GETS ORPHAN DRUG DESIGNATION IN ORGAN
TRANSPLANTATION.
Idun Pharmaceuticals, Inc., San Diego, Calif., has announced that
the U.S. Food and Drug Administration (FDA) has granted Orphan Drug
designation for the use of IDN-6556 to treat patients . . .
FDA CLEARS ENDOCARE TO MARKET CRYOCARE CS FOR PROSTATE
CANCER.
Endocare Inc., Irvine, Calif., an innovative medical device company
focused on the development of minimally invasive cryoablation
technologies for tissue and cancer tumor ablation, has announced . . .
IMMUNOMEDICS BUILDS MANUFACTURING PLANT AND PLANS TRIALS.
Immunomedics, Inc. (NASDAQ:IMMU) has successfully completed the
construction of its new large-scale antibody manufacturing facility at
its headquarters in Morris Plains, New Jersey. The new . . .
FDA EXTENDS TIMELINE FOR COMPLETION OF REMODULIN PHASE
IV.
United Therapeutics Corporation (NASDAQ:UTHR) has announced that
the U.S. Food and Drug Administration has issued new timelines for
completion of a required Phase IV postmarketing study to further . . .
VICAL GRANTS OPTION LICENSE TO MERCK FOR CANCER TARGETS.
Vical Incorporated (NASDAQ:VICL), San Diego, and Merck & Co.,
have amended their existing license agreement. Under the amended
agreement, Merck has obtained an option license for rights to . . .
BIOSANTE REPORTS SUPERIOR RESULT WITH BIOVANT.
BioSante Pharmaceuticals, Inc. (OTC BB: BISP), Lincolnshire, Ill.,
has reported results of several studies demonstrating the superiority of
its innovative calcium phosphate nanoparticulate (CAP) . . .
ATRIX SUBMITS IND FOR ATRIGEL FORMULATION OF OCTREOTIDE.
Atrix Laboratories, Inc. (Nasdaq: ATRX), Fort Collins, Colo., has
submitted an investigational new drug application (IND) to the U.S. Food
and Drug Administration for an Atrigel(R) formulation of . . .
MBI 226 STATISTICAL SUPERIORITY NOT ACHIEVED IN PHASE
III.
Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) and Fujisawa
Healthcare, Inc. have reported preliminary top line results from the MBI
226 Phase III trial which showed no statistically . . .
FDA CLEARS SANGSTAT'S TWO HYMOGLOBULIN IND
APPLICATIONS.
SangStat Medical Corporation (NASDAQ:SANG), Fremont, Calif., has
announced that the US Food and Drug Administration (FDA) has cleared two
Investigational New Drug (IND) applications for clinical . . .
NEXMED DEVELOPING TREATMENT FOR PREMATURE EJACULATION.
NexMed, Inc. (Nasdaq:NEXM), Robbinsville, NJ, a developer of
innovative transdermal treatments based on its NexACT proprietary drug
delivery technology, has reported progress in the development of . . .
|
|